Vasopressin administration facilitates fluid removal during hemodialysis

Kidney International

Volumn 71, Issue 4, 2007, Pages 318-324

  Van Der Zee, S ^a   Thompson, A ^a   Zimmerman, R ^a   Lin, J ^a   Huan, Y ^a   Braskett, M ^a   Sciacca, R R ^a   Landry, D W ^a   Oliver, J A ^a  

^a Howard Hughes Medical Institute   (United States)

Author keywords

Hemodialysis; Intradialytic hypotension; Vasopressin

Indexed keywords

ARGIPRESSIN; PLACEBO; VASOPRESSIN;

ADULT; ARTERIAL PRESSURE; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR EFFECT; CARDIOVASCULAR FUNCTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEHYDRATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG INFUSION; EXTRACELLULAR FLUID; FEMALE; HEMODIALYSIS; HUMAN; HYPERTENSION; HYPOTENSION; KIDNEY FAILURE; MALE; PRESSOR RESPONSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VASOPRESSIN BLOOD LEVEL; VASOPRESSIN RELEASE;

EID: 33846857256     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5001885     Document Type: Article

References (40)

1. Henderson LW. Symptomatic hypotension during hemodialysis. Kidney Int 1980; 17: 571-576.
2. Jaeger JQ, Mehta RL. Assessment of dry weight in hemodialysis: an overview. J Am Soc Nephrol 1999; 10: 392-403.
3. Hegstrom RM, Murray JS, Pendras JP et al. Two year's experience with periodic hemodialysis in the treatment of chronic uremia. Trans Am Soc Artif Intern Organs 1962; 8: 266-280.
4. Blumberg A, Nelp WB, Hegstrom RM, Scribner BH. Extracellular volume in patients with chronic renal disease treated for hypertension by sodium restriction. Lancet 1967; 8: 69-77.
5. Vertes V, Cangiano JL, Berman LB, Gould A. Hypertension in end-stage renal disease. N Engl J Med 1969; 280: 978-981.
6. Foley RN, Parfrey PS, Harnett JD et al. Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease. Kidney Int 1996; 49: 1379-1385.
7. Seliger SL, Gillen DL, Tirschwell D et al. Risk factors for incident stroke among patients with end-stage renal disease. J Am Soc Nephrol 2003; 14: 2623-2631.
8. US Renal Data System. USRDS 2004 Annual Data Report: Atlas of end-Stage Renal Diseases in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2004.
9. Mazzuchi N, Carbonell E, Fernandez-Cean J. Importance of blood pressure control in hemodialysis patient survival. Kidney Int 2000; 58: 2147-2154.
10. Groothoff JW, Gruppen MP, Offringa M et al. Mortality and causes of death of end-stage renal disease in children: A Dutch Cohort Study. Kidney Int 2002; 61: 621-629.
11. Stidley CA, Hunt WC, Tentori F et al. Changing relationship of blood pressure with mortality over time among hemodialysis patients. J Am Soc Nephrol 2006; 17: 513-520.
12. Endou K, Kamijima J, Kakubari Y, Kikawada R. Hemodynamic changes during hemodialysis. Cardiology 1978; 63: 175-187.
13. Rouby JJ, Rottembourg J, Durande JP et al. Hemodynamic changes induced by regular hemodialysis and sequential ultrafiltration hemodialysis: a comparative study. Kidney Int 1980; 17: 801-810.
14. Baldamus CA, Ernst W, Frei U, Koch KM. Sympathetic and hemodynamic response to volume removal during different forms of renal replacement therapy. Nephron 1982; 31: 324-332.
15. Santoro A, Mancini E, Spongano M et al. A haemodynamic study of hypotension during haemodialysis using electrical bioimpedance cardiography. Nephrol Dial Transplant 1990; 5(Suppl)1: 147-153.
16. Converse Jr RL, Jacobsen TN, Jost CM et al. Paradoxical withdrawal of reflex vasoconstriction as a cause of hemodialysis-induced hypotension. J Clin Invest 1992; 90: 1657-1665.
17. Landry DW, Levin HR, Gallant EM et al. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 1997; 95: 1122-1125.
18. Morales D, Madigan J, Cullinane S et al. Reversal by vasopressin of intractable hypotension in the late phase of hemorrhagic shock. Circulation 1999; 100: 226-229.
19. Horky K, Sramkova J, Lachmanova J et al. Plasma concentration of antidiuretic hormone in patients with chronic renal insufficiency on maintenance dialysis. Horm Metab Res 1979; 11: 241-246.
20. Fasanella d'Amore T, Wauters JP, Waeber B et al. Response of plasma vasopressin to changes in extracellular volume and/or plasma osmolality in patients on maintenance hemodialysis. Clin Nephrol 1985; 23: 299-302.
21. Hegbrant J, Thysell H, Martensson L et al. Changes in plasma levels of vasoactive peptides during standard bicarbonate hemodialysis. Nephron 1993; 63: 303-308.
22. Heintz B, Konigs F, Dakshinamurty KV et al. Response of vasoactive substances to intermittent ultrafiltration in normotensive hemodialysis patients. Nephron 1993; 65: 266-272.
23. Heintz B, Reiners K, Gladziwa U et al. Response of vasoactive substances to reduction of blood volume during hemodialysis in hypotensive patients. Clin Nephrol 1993; 39: 198-204.
24. Friess U, Rascher W, Ritz E, Gross P. Failure of arginine-vasopressin and other pressor hormones to increase in severe recurrent dialysis hypotension. Nephrol Dial Transpl 1996; 11: 402-403.
25. Uusimaa P, Huttunen K, Ruskoaho H et al. Neurohumoral responses to a single haemodialysis in chronic renal patients. Acta Physiol Scand 1999; 165: 25-31.
26. Landry DW, Oliver JA. The pathogenesis of vasodilatory shock. N Engl J Med 2001; 345: 588-595.
27. Dunn FL, Brennan TJ, Nelson AE, Robertson GL. The role of blood osmolality and volume in regulating vasopressin secretion in the rat. J Clin Invest 1973; 52: 3212-3219.
28. Aisenbrey GA, Handelman WA, Arnold P et al. Vascular effects of arginine vasopressin during fluid deprivation in the rat. J Clin Invest 1981; 67: 961-968.
29. Benmansour M, Rainfray M, Paillard F, Ardaillou R. Metabolic clearance rate of immunoreactive vasopressin in man. Eur J Clin Invest 1982; 12: 475-480.
30. Argent NB, Wilkinson R, Baylis PH. Metabolic clearance rate of arginine vasopressin in severe chronic renal failure. Clin Sci (Lond) 1992; 83: 583-587.
31. Rosa AA, Shideman J, McHugh R et al. The importance of osmolality fall and ultrafiltration rate on hemodialysis side effects. Influence of intravenous mannitol. Nephron 1981; 27: 134-141.
32. Weitzman RE, Reviczky A, Oddie TH, Fisher DA. Effect of osmolality on arginine vasopressin and renin release after hemorrhage. Am J Physiol 1980; 238: E62-E68.
33. Rysz J, Luciak M, Kedziora J et al. Nitric oxide release in the peripheral blood during hemodialysis. Kidney Int 1997; 51: 294-300.
34. Giusti-Paiva A, Ruginsk SG, de Castro M et al. Role of nitric oxide in lipopolysaccharide-induced release of vasopressin in rats. Neurosci Lett 2003; 346: 21-24.
35. Graybiel A, Glendy R. Circulatory effects following the intravenous administration of pitressin in normal persons and in patients with hypertension and angina pectoris. Am Heart J 1941; 21: 481-489.
36. Braunwald E, Wagner Jr HN. The pressor effect of the antidiuretic principle of the posterior pituitary in orthostatic hypotension. J Clin Invest 1956; 35: 1412-1418.
37. Padfield PL, Brown JJ, Lever AF et al. Changes of vasopressin in hypertension: cause or effect? Lancet 1976; 1: 1255-1257.
38. Minaker KL, Meneilly GS, Youn GJ et al. Blood pressure, pulse, and neurohumoral responses to nitroprusside-induced hypotension in normotensive aging men. J Gerontol 1991; 46: M151-M154.
39. Charra B, Calemard E, Cuche M, Laurent G. Control of hypertension and prolonged survival on maintenance hemodialysis. Nephron 1983; 33: 96-99.
40. Pierratos A, Ouwendyk M, Francoeur R et al. Nocturnal hemodialysis: three-year experience. J Am Soc Nephrol 1998; 9: 859-868.